OCS Oculis Holding AG IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1953530 · Reporting currency CHF · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CHF | 2025Q2*2025-06-30 | 2024Q2*2024-06-30 | 2023Q2*2023-06-30 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | 14.91M | 16.46M | 6.20M |
| SG&A expense | 6.12M | 6.26M | 4.80M |
| Operating income | -20.77M | -22.48M | -10.74M |
| Interest expense | 183,000 | 87,000 | 17,000 |
| Pretax income | -25.40M | -20.81M | -12.76M |
| Income tax | -24,000 | 30,000 | 114,000 |
| Net income | -25.38M | -20.84M | -12.88M |
| EPS (basic) | -0.49 | -0.51 | -0.38 |
| EPS (diluted) | -0.49 | -0.51 | -0.38 |
| Weighted avg. shares (diluted) | 52.29M | 40.54M | 33.57M |
| Balance sheet | |||
| Cash & equivalents | 64.27M | 43.85M | 41.93M |
| Current assets | 166.20M | 124.63M | — |
| PP&E, netmay include right-of-use assets (IFRS) | 441,000 | 249,000 | — |
| Intangibles | 13.29M | 12.21M | — |
| Total assets | 181.62M | 138.73M | — |
| Current liabilities | 36.55M | 23.63M | — |
| Total liabilities | 38.52M | 25.91M | — |
| Shareholders' equity | 143.10M | 112.83M | 117.20M |
| Cash flow statement | |||
| Operating cash flow | — | — | — |
| Stock-based compensation | — | 1.00M | — |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.